

University of Groningen

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines

Michaelis, M.; Kleinschmidt, M.C.; Barth, S.; Breitling, R.; Mayer, B.; Deubzer, H.; Witt, O.; Doerr, H.W.; Cinatl, J.; Cinatl Jr., J.

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2009

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Michaelis, M., Kleinschmidt, M. C., Barth, S., Breitling, R., Mayer, B., Deubzer, H., Witt, O., Doerr, H. W., Cinatl, J., & Cinatl Jr., J., (2009). *Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines*, 1 p.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

1211

POSTER

Peroxisome proliferator-activated receptor Gamma responsible for TGF β -induced epithelial mesenchymal transition (EMT) and tumor invasion of NSCLC cells (H460)

L.C. Lin¹, S.L. Hsu², C.L. Wu³, W.C. Liu¹, H.T. Chiu¹, C.M. Hsueh¹.

¹National Chung Hsing University, Department of Life Sciences, Taichung city, Taiwan; ²Taichung Veterans General Hospital, Department of Education and Research, Taichung city, Taiwan; ³Taichung Veterans General Hospital, Department of Internal Medicine, Taichung city, Taiwan

We have previously demonstrated that non-small cell lung cancer cell, H460, had strong drug resistance to TGF β and can grow and metastasize successfully in animal model. Despite the fact TGF β can suppress the growth of gastric carcinoma and hepatoma cells, it also promotes the epithelial mesenchymal transition (EMT) and/or metastasis of liver and breast cancers. We therefore were interested to know would TGF β also promote the EMT and invasion in NSCLC cells (H460) and exacerbate tumor metastasis. TGF β -triggered signaling pathway, P38/ERK/cPLA $_{2\alpha}$ /COX-2, and its downstream target, PPAR γ were also analyzed in H460 with or without TGF β to link with the induced EMT and/or tumor invasion. According to our early observation, PPAR γ was already known to play a critical role in the early development of TGF β resistance of H460. Our current results showed that TGF β -induced cell scattering of H460 first appeared at day 3 after the TGF β treatment followed by a morphological shift (from round to fibroblast or spindle-like shape) at day 7 and 14. The results clearly demonstrated a TGF β -induced EMT in H460. Seven days after TGF β treatment, the migration and invasion of H460 were significantly increased in accompany with the induced expression of PPAR γ and cell survival. The up-stream regulators (P38, ERK, cPLA $_{2\alpha}$ and COX-2) of PPAR γ were also activated (phosphorylated) by TGF β at early time points (1–6 h). To further confirm the role of PPAR γ in TGF β -induced EMT and cell invasion in H460, we added PPAR γ inhibitor (GW9662) into TGF β -treated H460 and found that not only survival of H460 was decreased, TGF β -induced EMT and cell invasion were also interrupted. The results suggested that PPAR γ was critical in the protection of H460 from TGF β -mediated growth inhibition and also promoted TGF β -induced EMT and cell invasion in H460. In overall, TGF β -induced EMT and cell invasion in H460 have been confirmed and proved to be PPAR γ dependent. Results from the study not only provided information about the drug resistance and metastasis of H460 in response to TGF β treatment but also implied the therapeutic value of PPAR γ inhibitor (GW9662) in the treatment of NSCLCs.

1212

POSTER

A novel mitotic kinesin Eg5 inhibitor exerts the growth inhibitory effect on cancer cells in a manner independent of neither Eg5 expression level nor induction of monoastrol formation

H. Lee¹, N. Ogo², A. Asai², N. Boku³, Y. Koh¹. ¹Shizuoka Cancer Center Research Institute, Drug Discovery and Development Division, Shizuoka, Japan; ²Graduate School of Pharmaceutical Sciences University of Shizuoka, Center for Drug Discovery, Shizuoka, Japan; ³Shizuoka Cancer Center, Gastrointestinal Division, Shizuoka, Japan

Background: Mitotic kinesin Eg5 plays an important role in mitosis, as it is critical for proper bipolar spindle assembly. After the discovery of the first Eg5 inhibitor monastrol, a number of Eg5 inhibitors have been developed as anticancer drugs. We have synthesized a series of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors and showed potent growth inhibitory effect on cancer cells and induction of monoastrol formation.

Materials and Methods: Growth inhibitory effects of monastrol and STLC derivatives, Compound1, Compound2 and Compound3 were evaluated by MTT assay in MKN1, MKN45, MKN74, NUGC3, NUGC4, NCI-N87 gastric cancer cell lines, C170, DLD1, HCT15, COLO205 colon cancer cell lines and AsPC1, BxPC3, SUI2 pancreatic cancer cell lines. Cell cycle analysis and immunocytochemistry were carried out to evaluate the induction of mitotic arrest and monoastrol formation, respectively. Expression levels of Eg5, BubR1 and MAD2 were evaluated by western blot for a predictive biomarker study.

Results: Among the derivatives, Compound3 showed the most potent growth inhibitory effect with IC50 s ranging from 0.16 to 0.89 mM except for AsPC3 cells, while monastrol showed almost no effect at concentrations up to 10 mM. Compound3 induced G2/M arrest as early as 8 hours after the treatment at a concentration of IC50. Induction of monoastrol formation was modestly observed in BxPC3 and HCT15 cells which are sensitive to, Compound3, while it was also observed in AsPC3 cells which are not sensitive to Compound3 with an IC50 of around 10 mM. There was no correlation observed between the growth inhibitory effect and the Eg5 expression level and no significant change was observed in the BubR1 or MAD2 expression level after the treatment, either.

Conclusions: It is suggested that Compound3 should be considered for further exploration and development and that induction of monoastrol formation may not work as a predictive biomarker. Taken together, a novel mitotic kinesin Eg5 inhibitor Compound3 may have other mechanisms of action for its growth inhibitory effect on cancer cells and further investigation on alternative biomarkers is necessary to develop Eg5 inhibitors as an anticancer drug.

1213

POSTER

Plumbagin induces ROS-mediated apoptosis in human myeloid leukaemia cells in vivo

K.H. Xu¹, D.P. Lu¹. ¹Institute of Hematology, Peking University, Beijing, China

Plumbagin, a naphthoquinone from the roots of *Plumbago zeylanica*, known to possess anticancer and antibacterial activity. Based on the former finding in vitro, we further investigated the effects of Plumbagin on the growth of human myeloid leukemia NB4 cells that had been transplanted subcutaneously into NOD/SCID mice.

Material and Methods: In order to elucidate the molecular mechanism involved in plumbagin-induced apoptosis, we studied the effect of Plumbagin with IC50 (9 μ M) by monitoring the activity of the caspase-3 and caspase-9, the change of mitochondrial membrane potential ($\Delta\Psi$ m), the expression of the Bcl-2 family as well as ROS change in plumbagin-induced apoptosis. The efficacy of Plumbagin in vivo was evaluated with intraperitoneal injection of plumbagin (2 mg/kg body weight) daily for three weeks using subcutaneous NB4 xenograft in NOD/SCID mice, comparing with the vehicle and Doxorubicin (1 mg/kg thrice a week). The tissue sections were applied to hematoxylin and eosin histological staining as well as TUNEL assay.

Results: We revealed that plumbagin triggered the mitochondrial apoptotic pathway, as indicated by the increase in Bax/Bcl-2 ratios, resulting in mitochondrial membrane potential loss, and corresponding caspase activation. We also found that the generation of ROS was a critical mediator in plumbagin-induced cell apoptosis, which would be abrogated completely by the antioxidant, NAC. Furthermore, compared with the control, Plumbagin presented a ~60% reduction of tumor volume and marked increase in tumor apoptosis; There was no overt manifestation of toxicity such as weight loss, tissue damage and behavior change as showed in Doxorubicin-treated mice.

Conclusion: Our data support that Plumbagin has potential as a novel therapeutic agent for myeloid leukemia with minimal side-effects.

1214

POSTER

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines

M. Michaelis¹, M.C. Kleinschmidt¹, S. Barth², R. Breitling³, B. Mayer⁴, H. Deubzer⁵, O. Witt⁵, H.W. Doerr¹, J. Cinatl¹, J. Cinatl Jr.¹.

¹Universitätsklinikum, Institut Für Medizinische Virologie, Frankfurt Am Main, Germany; ²Blue-Drugs GmbH, Research, Frankfurt Am Main, Germany; ³University Of Groningen, Groningen Bioinformatics Center, Groningen, The Netherlands; ⁴Emergentec Biodevelopment GmbH, Research, Vienna, Austria; ⁵DKFZ, Klinische Kooperationsseinheit Pädiatrische Onkologie (g340) and Pädiatrie III, Heidelberg, Germany

Background: Artemisinin derivatives are well-tolerated anti-malaria drugs that also exert anti-cancer activity. Here, we investigated artemisinin and its derivatives dihydroartemisinin and artesunate in a panel of chemosensitive and chemoresistant human neuroblastoma cells as well as in primary neuroblastoma cultures.

Materials and Methods: Cell viability was determined by MTT assay or by determination of ATPase activity. Apoptosis was examined by staining for activated caspase-3 and detection of cells with low DNA content (sub-G1) by flow cytometry. Bioinformatic analysis of gene microarray data was used to identify genes relevant for neuroblastoma cell response to artesunate.

Results: Only dihydroartemisinin and artesunate affected neuroblastoma cell viability with artesunate being more active. Of 16 cell lines and two primary cultures, only UKF-NB-3' CDDP¹⁰⁰⁰ showed low sensitivity to artesunate. Artesunate induced apoptosis and reactive oxygen species in neuroblastoma cells. L-Buthionine-S,R-sulfoximine, an inhibitor of GCL (glutamate-cysteine ligase), resensitized in part UKF-NB-3' CDDP¹⁰⁰⁰ cells to artesunate. This finding together with bioinformatic analysis of expression of genes involved in glutathione metabolism showed that this pathway is involved in artesunate resistance.

Conclusion: These data indicate that neuroblastoma represents a artesunate-sensitive cancer entity including chemoresistant cells. Characteristic gene expression signatures based on a previous analysis of artesunate resistance in the NCI60 cell line panel clearly separated UKF-NB-3' CDDP¹⁰⁰⁰ from the other cell lines.